What Is the Global Artificial Intelligence In Drug Discovery Market Size, Trends & Forecast to 2025

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA3597

Publication Date: May 2025

Artificial Intelligence In Drug Discovery Market Size Growth Rate

As per 6Wresearch, Global Artificial Intelligence In Drug Discovery Market size is projected to reach USD 15.7 billion by 2031, growing at a CAGR of 8.57% from 2025 to 2031. This is driven by advancements in machine learning algorithms.

What Is the Global Artificial Intelligence In Drug Discovery Market Size?

The global artificial intelligence (AI) in drug discovery market has witnessed remarkable growth in recent years and is projected to expand significantly in the coming decades. With the integration of advanced algorithms and machine learning models, AI is revolutionizing the pharmaceutical and biotechnology sectors. The growth is attributed to increasing demand for more efficient drug discovery strategies, the growing number of complex diseases such as cancer and neurological disorders, and a pressure to decrease R&D budgets. Market players continue to realize AI solutions that can predict drug behavior, expedite clinical trials, or identify viable candidates, further changing the industry.

Embrace AI for Efficient Drug Development

Artificial intelligence offers transformative potential to improve the speed and efficiency of drug development. Traditionally, drug discovery can take years (and significant financial cost) to find, validate, and develop a viable candidate. AI-enabled tools can analyze extremely large datasets to identify promising compounds and even predict outcomes, all in much shorter time frames. AI can improve accuracy throughout the life of a drug from the early stages of discovery through clinical trials, allowing researchers better ability to make data-driven decisions. This means less cost, less trial-and-error experimentation while searching for better treatment options, and quicker time-to-market for life-changing and life-saving medications. With AI, pharmaceutical companies can spend more time on developing exciting new therapies, personalized for a patient population, which will help improve health care around the world.

Transforming Pharma: AI's Role in Next-Gen Drug Development

The pharmaceutical industry is being reshaped in depth to utilize artificial intelligence for next-gen drug development. Naturally, next-gen drug development relates to utilizing both computational biology, predictive modeling, and virtual screening to uncover the right drug candidates and avoid labor-intensive lab work that is also costly. AI ultimately drives personalized medicine by taking into account the patient's genetics, medications, and environment, and will deliver drugs closer to patients with the maximum utility. Furthermore, AI can greatly benefit clinical trials: patient recruitment, early identification of potential side effects, and monitoring the clinical trials to expedite the entire process, All these advanced techniques and technologies will both decrease and improve the safety and efficacy of any resulting therapy propel us speedily into a new smarter and more data-informed time in "medical" innovation.